相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Japanese gastric cancer treatment guidelines 2018 (5th edition)
GASTRIC CANCER (2021)
Impact of postoperative complications on survival outcomes in patients with gastric cancer: exploratory analysis of a randomized controlled JCOG1001 trial
Masanori Tokunaga et al.
GASTRIC CANCER (2021)
Prognostic significance of pre- and post-operative tumour markers for patients with gastric cancer
Jun-Peng Lin et al.
BRITISH JOURNAL OF CANCER (2020)
Prognostic value of postoperative C-reactive protein elevation versus complication occurrence: a multicenter validation study
Yukinori Kurokawa et al.
GASTRIC CANCER (2020)
Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years
Yonghoon Choi et al.
GASTRIC CANCER (2020)
EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer
Guoliang Wang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Circulating Exosomal Gastric Cancer-Associated Long Noncoding RNA1 as a Bioniarker for Early Detection and Monitoring Progression of Gastric Cancer A Multiphase Study
Xin Guo et al.
JAMA SURGERY (2020)
Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis
Yibo Fan et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Quantitative evidence for early metastatic seeding in colorectal cancer
Zheng Hu et al.
NATURE GENETICS (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth
Yi Yang et al.
CELL RESEARCH (2018)
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Franz L. Ricklefs et al.
SCIENCE ADVANCES (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Implications of NOVA1 suppression within the microenvironment of gastric cancer: association with immune cell dysregulation
Eun Kyung Kim et al.
GASTRIC CANCER (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
Stephan Kruger et al.
ONCOIMMUNOLOGY (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer
Fan Feng et al.
BMC CANCER (2017)
PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
Yanhua Bai et al.
DIAGNOSTIC PATHOLOGY (2017)
Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria
Hiroshi Katayama et al.
SURGERY TODAY (2016)
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
Fabian Finkelmeier et al.
EUROPEAN JOURNAL OF CANCER (2016)
Exosomes and tumor-mediated immune suppression
Theresa L. Whiteside
JOURNAL OF CLINICAL INVESTIGATION (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib
Steffen Filskov Sorensen et al.
LUNG CANCER (2016)
PD-L1 expression in human cancers and its association with clinical outcomes
Xin Wang et al.
ONCOTARGETS AND THERAPY (2016)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
D. Rossille et al.
LEUKEMIA (2014)
Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects
Alexander L. Rakhmilevich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2012)
Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
Xavier Frigola et al.
CLINICAL CANCER RESEARCH (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Minimal Residual Disease (MRD) in Gastric Carcinoma - an Overview
B. Garlipp et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2011)
分享论文
